Tricyclic compound
US-9475805-B2 · Oct 25, 2016 · US
Process for bendamustine hydrochloride
US9273010B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9273010-B2 |
| Application number | US-201214127425-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2012 |
| Priority date | Jun 20, 2011 |
| Publication date | Mar 1, 2016 |
| Grant date | Mar 1, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a process for the preparation of 1H-benzimidazol-1-methyl-5-N,N-di(2-hydroxyethyl)-2-butanoic acid ethyl ester. The present invention also provides a process for the preparation of bendamustine hydrochloride. The present invention further provides a process for the purification of bendamustine hydrochloride.
First claim
Opening claim text (preview).
We claim: 1. A process for the preparation of 1H-benzimidazol-1-methyl-5-N,N-di-(2-hydroxyethyl) amino-2-butanoic acid ethyl ester, comprising reacting 1H-benzimidazol-1-methyl-5-amino-2-butanoic acid ethyl ester with ethylene oxide in the presence of an acid to form 1H-benzimidazol-1-methyl-5-N,N-di-(2-hydroxyethyl) amino-2-butanoic acid ethyl ester, wherein the amount of ethylene oxide is 6.0 to 7.5 moles with respect to 1H-benzimidazol-1-methyl-5-amino-2-butanoic acid ethyl ester. 2. The process as claimed in claim 1 , wherein the amount of ethylene oxide is 7.0 to 7.5 moles with respect to 1H-benzimidazol-1-methyl-5-amino-2-butanoic acid ethyl ester. 3. The process as claimed in claim 1 , wherein the acid used in the process is acetic acid.
Assignees
Inventors
Classifications
- C07D235/16Primary
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9273010B2 cover?
- The present invention provides a process for the preparation of 1H-benzimidazol-1-methyl-5-N,N-di(2-hydroxyethyl)-2-butanoic acid ethyl ester. The present invention also provides a process for the preparation of bendamustine hydrochloride. The present invention further provides a process for the purification of bendamustine hydrochloride.
- Who is the assignee on this patent?
- Reddy Bandi Parthasaradhi, Reddy Kura Rathnakar, Reddy Dasari Muralidhara, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07D235/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).